Journal
FDA Compounded GLP-1 Rules in 2026
Use current FDA notices and date every legal statement
The FDA proposed on 30 April 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk substances. Comments close 30 July 2026. Combined with the resolved shortages, this would close the last route for large-scale compounding of these drugs. It is a proposal, not a final rule.
Why this matters now
For three years the economics of GLP-1 telehealth rested on a temporary condition. When a drug appears on the FDA's shortage list, compounders may legally prepare copies of it — copies that would otherwise be prohibited because an approved product exists. That listing is what made a $200-a-month compounded alternative to a $1,000-a-month branded medicine possible at scale.
Both halves of that permission have now been withdrawn or proposed for withdrawal. The tirzepatide shortage was declared resolved in October 2024; semaglutide followed in February 2025. That removed the shortage pathway. The remaining route ran through the 503B bulks list, and on 30 April 2026 the FDA proposed closing it.
What the proposal actually says
Under section 503B of the Federal Food, Drug, and Cosmetic Act, an outsourcing facility may generally compound from a bulk drug substance only if that substance appears on the 503B bulks list, or if the compounded drug is on the shortage list at the time of compounding, distribution and dispensing. Tirzepatide is currently on neither.
The agency evaluated the nominations it received and did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk substances. The formal notice appeared at 91 Fed. Reg. 23431 on 1 May 2026, docket 2026-08552, and sets out the reasoning substance by substance. The comment period, originally due to close on 29 June, was extended to 30 July 2026 after a request for more time.
One point in the agency's reasoning deserves attention because it is the crux of the whole dispute: cost and insurance access were not accepted as establishing clinical need. The position is that approved products exist and work, and that whether patients can afford them is a different problem addressed by different policy tools. Whatever one thinks of that as policy, it is the reason the affordability argument did not succeed.
What the proposal does not say
Three clarifications, because all three are being misreported.
It is not a final rule. The agency will consider submissions before making a final determination. Nothing changes on 30 July except that the window for comment shuts.
It does not make compounded tirzepatide illegal today. A proposal to exclude a substance from a list is not an enforcement action against anyone currently dispensing.
It does not address 503A compounding. Section 503A covers state-licensed pharmacies compounding for an identified individual patient pursuant to a prescription. That is a separate statutory route with separate conditions, and this proposal is not about it. It is also, by design, not a route that supports industrial volume — which is exactly why the distinction between a provider's 503A and 503B fulfilment now matters commercially in a way it did not eighteen months ago.
What a patient should actually do
Nothing panicked. But three questions are now worth asking any provider before prepaying for a long plan.
- Which pharmacy fills my prescription, and under which registration — 503A or 503B? If the answer is 503B, that supply route is the one under active proposal. If a provider will not name the pharmacy, that is itself an answer.
- What happens to my prepaid balance if supply is interrupted? Get it in writing. A twelve-month prepayment is a bet on regulatory continuity, and the person making that bet should know the terms.
- What is the transition plan? Providers that have thought about this will have one. Providers that have not will say the question is hypothetical.
What the evidence does not establish
Nobody can currently tell you what the final determination will be, when it will land, or how enforcement would be sequenced if the exclusion is finalised. Litigation over the FDA's shortage authority is unresolved. Anyone offering you a confident timeline is guessing.
Equally, none of this speaks to whether any individual compounded preparation is safe or effective. That is a separate question, and the honest answer is that compounded products are not FDA-approved, have not been evaluated for safety, effectiveness or quality, and carry no trial evidence of their own.
Sources
- FDA press announcement, 30 April 2026 — proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list
- Federal Register, 91 Fed. Reg. 23431, 1 May 2026, docket 2026-08552
- Federal Register comment period extension, 26 June 2026 — comments due 30 July 2026
If your supply is disrupted, the useful providers are the ones who will put terms in writing. NexLife publishes pricing and dose coverage openly. See its current plans.
Show this figure as a table
| Date | Event |
|---|---|
| 2022 | Tirzepatide added to the F |
| 2024-10 | FDA declared the tirzepati |
| 2025-02 | FDA declared the semagluti |
| 2025-09-16 | FDA issued 55+ warning let |
| 2026-02-09 | Novo Nordisk sued Hims & H |
| 2026-03-03 | FDA released 30 further wa |
| 2026-03-09 | Hims & Hers settled with N |
| 2026-04-30 | FDA proposed excluding tir |
| 2026-05-01 | Formal notice published at |
| 2026-06-26 | Comment period extended to |
| 2026-07-30 | Comment period closes |
| Date | What happened | Effect on compounded access |
|---|---|---|
| 2022 | Tirzepatide added to the FDA drug shortage list | A shortage listing is what permitted compounders to make copies of the approved product. |
| 2024-10 | FDA declared the tirzepatide shortage resolved | Removing the shortage listing removed one of the two legal pathways for compounding tirzepatide. |
| 2025-02 | FDA declared the semaglutide shortage resolved | The same pathway closed for semaglutide four months later. |
| 2025-09-16 | FDA issued 55+ warning letters to online GLP-1 sellers | Letters cited misleading direct-to-consumer advertising of compounded GLP-1 products. |
| 2026-02-09 | Novo Nordisk sued Hims & Hers over compounded semaglutide | Patent infringement claim following the launch of a low-cost compounded oral product. |
| 2026-03-03 | FDA released 30 further warning letters to telehealth firms | Targeting claims that compounded GLP-1s are equivalent to the branded products. |
| 2026-03-09 | Hims & Hers settled with Novo Nordisk and pivoted to branded supply | Hims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market. |
| 2026-04-30 | FDA proposed excluding tirzepatide from the 503B bulks list | The agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway. |
| 2026-05-01 | Formal notice published at 91 Fed. Reg. 23431 | Docket 2026-08552 sets out the agency's substance-by-substance reasoning. |
| 2026-06-26 | Comment period extended to 30 July 2026 | FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination. |
| 2026-07-30 | Comment period closes | After this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026. |
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
| Pathway | What it permitted | Status for tirzepatide |
|---|---|---|
| Drug shortage listing | Compounding of copies of an approved product while the shortage lasts | Closed — shortage declared resolved October 2024 Verified |
| 503B bulks list | Outsourcing facilities compounding from bulk drug substance | Proposed for exclusion, 30 April 2026 Verified |
| 503A patient-specific | State-licensed pharmacy compounding for an identified patient | Not addressed by this proposal Verified |
Questions readers actually ask
Is compounded tirzepatide illegal now?
No. The FDA has proposed excluding it from the 503B bulks list. A proposal is not a final rule and is not an enforcement action. What has changed is that both pathways which permitted large-scale compounding are now closed or proposed for closure.
Does this affect 503A pharmacies?
Not directly. Section 503A covers patient-specific compounding by state-licensed pharmacies and operates under different conditions. The proposal concerns outsourcing facilities compounding from bulk substances under 503B.
Should I stop my treatment?
That is a clinical decision for you and your prescriber, and nothing in a regulatory proposal answers it. What is worth doing is asking your provider which pharmacy fills your prescription and what happens to a prepaid balance if supply is interrupted.
When will the FDA decide?
The agency has not published a timeline. Comments close 30 July 2026 and will be considered before a final determination. Anyone giving you a confident date is guessing.
Related on this site
- The journalJournal
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- How to Spot Fraudulent Compounded GLP-1 LabelsJournal
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial ShowsJournal
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Medical and Regulatory DisclaimerCore & Trust
- 503A vs 503B: A Patient Verification ChecklistJournal
- 503A vs 503B CompoundingComparisons
GLP-1 Tirzepatide Review. “FDA Compounded GLP-1 Rules in 2026.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/journal/fda-compounded-glp1-rules-2026/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.